Electrospray Ionisation Mass Spectrometry Facilitates Detection of Fibrinogen (Bβ 14 Arg → Cys) Mutation in a Family with Thrombosis

Summary

We report the first direct detection of a fibrinogen mutation by electrospray ionisation mass spectrometry. The propositus, from a family with a history of thrombosis, came to attention after a pulmonary embolism subsequent to a spontaneous abortion. Prolonged thrombin (41 s) and reptilase times (26 s) together with an impairment of fibrinopeptide B release suggested a mutation at the thrombin cleavage site of the Bβ chain. Direct mass analysis of purified fibrin chains from a thrombin induced clot showed that 50% of the Bβ chains remained uncleaved. The measured mass of the mono sialo isoform of this uncleaved chain was 54150 Da, compared to a value of 54198 Da for normal Bp chains. This decrease of 48 Da in the intact protein is indicative of either a Bβ 14 Arg to Cys, or Arg to Leu substitution. Heterozygosity for the Bβ 14 Arg → Cys mutation was verified by PCR amplification and DNA sequence analysis.

• References

• 1 Smith RD, Loo JA, Edmonds CG, Barinaga CJ, Udseth HR. New developments in biochemical mass spectrometry: electrospray ionization. Anal Chem 1990; 62: 882-899
• 2 Green BN, Jones AT, Roberts NB. Electrospray mass spectrometric evidence for the occurrence of two major variants in native pig pepsin A. BiochemJ 1996; 313: 241-244
• 3 Witkowska HE, Bitsch F, Shackleton CHL. Expediting rare variant hemoglobin characterization by combined HPLC/electrospray mass spectrometry. Hemoglobin 1993; 17: 227-242
• 4 Brennan SO. Electrospray ionization analysis of human fibrinogen. Thromb Haemost 1997; 78: 1055-1058
• 5 Haverkate F, Samama M. Familial dysfibrinogenaemia and thrombophilia: Report on a study of the SSC subcommittee on fibrinogen. Thomb Haemost 1995; 73: 151-161
• 6 Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Krest AFJA, Lord ST. Abnormal fibrinogens IJmuiden (Bβ 14 Arg -> Cys) and Nijmegen (Bβ 44 Arg -> Cys) form disulfide-linked fibrinogen albumin complexes. Proc Natl Acad Sci USA 1992; 89: 3478-3482
• 7 Branson HE, Schmer G, Theodor I, Pirkle TH. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B. Acta Haematol 1983; 79: 257-263
• 8 Kaudewitz H, Henschen A, Soria C, Soria J, Bertrand O, Heaton D. The molecular defect of the genetically abnormal fibrinogen Christchurch II. In: Fibrinogen and its Derivatives Muller-Berghaus G, Scheefers-Brochel V, Sellmayn E, Henschen A. eds Elsevier Science Publishers BV. 1986. pp 31-36
• 9 Brennan SO, Hammonds B, George PM. Aberrant hepataic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα 20 Val -> Asp). J Clin Invest 1995; 96: 2854-2858
• 10 Henschen A, McDonagh J. Fibrinogen, fibrin and factor Xffl. In: Blood Coagulation Zwaal RFA, Hemker HC. eds Elsevier Science Publishers Amsterdam BV. 1986. pp 171-241
• 11 Martinez J, Palascak J, Peters C. Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med 1977; 89: 367-377
• 12 Soria J, Soria C, Samama M, Poirot E, Kling C. Fibrinogen Troyes-fibrinogen Metz. Two new cases of congenital dysfibrinogenemia. Thromb Diath Haemorrh 1972; 27: 619-633
• 13 al Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-347